EDVance EDV2209 – a Paradigm shift in the treatment of stroke.
- Coordinator
- Edvince Aktiebolag, Sweden
- Runs
- 1 January 2022 to 31 October 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €4.4m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190148437
What the project is doing
In the project's own words, from its summary on CORDIS.
Despite tremendous research efforts and a large number of clinical trials focused on developing treatments for stroke, the field's current state remains dismal. There are, at present, no efficient treatments nor promising drug candidates for this lethal and disabling condition. A different perspective with a new approach is therefore desperately needed. Edvince's drug discovery and development is born out of founder and Professor Lars Edvinsson's extensive, fundamental and pioneering research of cerebral circulation, receptor regulation, stroke and migraines.
Edvince is now ready to conduct the first clinical trial in 2022 with its innovative and disruptive lead drug EDV2209, an orphan drug for the treatment of brain ischemia associated with severe subarachnoid hemorrhage (SAH). The drug helps to keep the blood vessels in the brain open, allowing brain cells to receive oxygen and nutrients to prevent brain damage.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Edvince Aktiebolag | Lund | Sweden | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI